Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
Sinclair (SBGI)
Consensus Price Target: $17.86 (29% implied return)
With over 2,400 hours of local news produced weekly and 640 broadcast channels reaching millions of American homes, Sinclair (NASDAQ: SBGI) operates a network of 185 local television stations across 86 U.S. markets, producing news programming and distributing content from major networks.
Why Should You Dump SBGI?
- Annual sales declines of 11.8% for the past five years show its products and services struggled to connect with the market during this cycle
- Eroding returns on capital suggest its historical profit centers are aging
- High net-debt-to-EBITDA ratio of 8× increases the risk of forced asset sales or dilutive financing if operational performance weakens
Sinclair is trading at $13.84 per share, or 21.1x forward P/E. Check out our free in-depth research report to learn more about why SBGI doesn’t pass our bar.
Charter (CHTR)
Consensus Price Target: $275.47 (24.9% implied return)
Operating as Spectrum, Charter (NASDAQ: CHTR) is a leading telecommunications company offering cable television, high-speed internet, and voice services across the United States.
Why Do We Pass on CHTR?
- Performance surrounding its internet subscribers has lagged its peers
- Free cash flow margin is forecasted to grow by 1.6 percentage points in the coming year, potentially giving the company more chips to play with
- Unchanged returns on capital make it difficult for the company’s valuation multiple to re-rate
At $220.62 per share, Charter trades at 5.1x forward P/E. If you’re considering CHTR for your portfolio, see our FREE research report to learn more.
Evolent Health (EVH)
Consensus Price Target: $5.18 (102% implied return)
Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.
Why Are We Wary of EVH?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 2.3% annually over the last two years
- Negative returns on capital show management lost money while trying to expand the business, and its shrinking returns suggest its past profit sources are losing steam
- High net-debt-to-EBITDA ratio of 6× could force the company to raise capital at unfavorable terms if market conditions deteriorate
Evolent Health’s stock price of $2.56 implies a valuation ratio of 15x forward P/E. To fully understand why you should be careful with EVH, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
